Quantum Genomics Secures €3 Million Non-dilutive Financing

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC)

, a biopharmaceutical company specializing in the development of a new class of drugs that directly targets the brain to treat difficult-to-treat/resistant hypertension and heart failure, today announced it has secured €3 million in non-dilutive financing through grants from the French government and BNP bank and an R&D loan from Bpifrance.

BNP bank has granted a €1.5 million loan, guaranteed by the French government (PGE) with an initial 12 months maturity, at a rate of 0.25%. The Company has been given the option to request 5 years’ amortization.

Bpifrance has granted a €1.5 million innovation and R&D loan for a period of 7.6 years at an interest rate of 0.72%. First reimbursement is scheduled on December 31, 2023.

“We would like to thank the French government, Bpifrance and our banking partners for their support in this financing. This additional non-dilutive financing, which processes were initiated last November 2020, secured our treasury in a context which remain uncertain. This comes at an important time for our Company, following our recent capital raise in December 2020 and the signing of various partnerships with various strategic partners in 2020, all of which will serve to strengthen and accelerate our R&D programs,” said Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics.

About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).

For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn

Contacts

Quantum Genomics
[e-mail]
So Bang (EUROPE)
Financial and Media [e-mail]
LifeSci (USA)
Mike TattoryMedia Relations and Scientific communications+1 [phone] - [e-mail]